{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"100","upperLimit":"100","value":"100"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive palbociclib PO QD on days 1-21. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment (Palbociclib)"}],"paramType":"NUMBER","populationDescription":"Three patients did not receive any protocol therapy and are excluded from this analysis.","reportingStatus":"POSTED","timeFrame":"From enrollment to 30 days after the end of treatment, up to 2 years","title":"Percentage of Patients Experiencing Grade 3 or Higher Adverse Events","type":"SECONDARY","unitOfMeasure":"percentage of participants"}